miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells

Cancer Research

Volumn 75, Issue 9, 2015, Pages 1859-1867

  Zhang, Jing ^a   Jiao, Jingjing ^a   Cermelli, Silvia ^b   Muir, Kyle ^b   Jung, Kwang Hwa ^a   Zou, Ruhai ^a,c   Rashid, Asif ^a   Gagea, Mihai ^a   Zabludoff, Sonya ^d   Kalluri, Raghu ^a   Beretta, Laura ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d REGULUS THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD51 ANTIGEN; MICRORNA 21; NOTCH2 RECEPTOR; OSTEOPONTIN; CD24 ANTIGEN; MICRORNA; MIRN21 MICRORNA, MOUSE; NOTCH2 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, MOUSE; SPP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD24+ PROGENITOR CELL; CELL EXPANSION; CELL FUNCTION; CELL SURVIVAL; CONTROLLED STUDY; GENE DELETION; GENE FUNCTION; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; NOTCH2 GENE; ONCOGENE; PRIORITY JOURNAL; PTEN GENE; STEM CELL; STROMA CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CANCER STEM CELL; CARCINOGENESIS; GENETICS; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD24; APOPTOSIS; CARCINOGENESIS; CELL SURVIVAL; INTEGRIN ALPHAV; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; NEOPLASTIC STEM CELLS; OSTEOPONTIN; PTEN PHOSPHOHYDROLASE; RECEPTOR, NOTCH2;

EID: 84933036440     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1254     Document Type: Article

References (38)

1. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011; 8: 706-13.
2. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
3. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-89.
4. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419-27.
5. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008; 47: 1955-63.
6. Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, et al. microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol 2010; 6: 402.
7. Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics. FEBS J 2011; 278: 1598-609.
8. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008; 12: 2189-204.
9. Mizuguchi Y, Mishima T, Yokomuro S, Arima Y, Kawahigashi Y, Shigehara K, et al. Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma. PLoS ONE 2011; 6: e15304.
10. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303.
11. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, Mori Y, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009; 49: 1595-601.
12. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456: 980-4.
13. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-97.
14. Marquez RT, Bandyopadhyay S, Wendlandt EB, Keck K, Hoffer BA, Icardi MS, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90: 1727-36.
15. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
16. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J, et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004; 113: 1774-83.
17. Stiles B, Wang Y, Stahl A, Bassilian S, Lee WP, Kim YJ, et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 2004; 101: 2082-7.
18. Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009; 77: 910-9.
19. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-42.
20. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647-58.
21. Zhou L, Yang ZX, Song WJ, Li QJ, Yang F, Wang DS, et al. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol 2013; 43: 661-9.
22. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63.
23. Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu T, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 2014; 35: 537-45.
24. Bourguignon LY, Earle C, Wong G, Spevak CC, Krueger K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012; 31: 149-60.
25. Kohanbash G, Okada H. MicroRNAs and STAT interplay. Semin Cancer Biol 2012; 22: 70-5.
26. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110: 1330-3.
27. Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a sup-pressive negative feedback on IFN-induced apoptosis. Cancer Res 2010; 70: 8108-16.
28. Jeliazkova P, Jors S, Lee M, Zimber-Strobl U, Ferrer J, Schmid RM, et al. Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1. Hepatology 2013; 57: 2469-79.
29. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notchmediated conversion of hepatocytes. J Clin Invest 2012; 122: 3914-8.
30. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012; 122: 2911-5.
31. Dill MT, Tornillo L, Fritzius T, Terracciano L, Semela D, Bettler B, et al. Constitutive Notch2signaling induceshepatic tumorsinmice. Hepatology 2013; 57: 1607-19.
32. Razumilava N, Gores GJ. Notch-driven carcinogenesis: The merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype. J Hepatol 2013; 58: 1244-5.
33. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012; 143: 1660-9 e7.
34. Chen Y ZS, Qi D, Zheng S, Guo J, Zhang S, Weng Z. Inhibition of Notch signaling by a g-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS ONE 2013; 7: 11.
35. He Y, Huang C, Li J. miR-21 is a critical therapeutic target for renal fibrosis. Cell Biochem Biophys 2014; 68: 635-6.
36. Noetel A, Kwiecinski M, Elfimova N, Huang J, Odenthal M. microRNA are central players in anti- and profibrotic gene regulation during liver fibrosis. Front Physiol 2012; 3: 49.
37. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res 2014; 44: 22-30.
38. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology 2012; 55: 483-90.